Lichen sclerosus et atrophicus induced by carbamazepine: a case report.
We report a case of Lichen Sclerosus in a 73-year-old man who had been treated for epilepsy with carbamazepine. Lichen sclerosus et atrophicus (LSA), also called lichen sclerosus (LS), is a chronic inflammatory cutaneous condition characterized by white plaques with epidermal atrophy and scarring. To date no cases of LSA has been linked to carbamazepine, although in a few cases lichenoid eruptions but without sclero-atrophy have been described after exposure to this drug. Therefore, to our knowledge, this is the first report of a Lichen sclerosus et atrophicus induced by carbamazepine.
Dermatology Unit, NESMOS Department, II School of Medicine, Sapienza University Rome, S. Andrea Hospital, Rome, Italy.
G
G
Pranteda
M
M
Muscianese
M
M
Grimaldi
L
L
Fidanza
G
G
Pranteda
A
A
Narcisi
S
S
Nistico
U
U
Bottoni
D000287:Administration, Topical; D000368:Aged; D000927:Anticonvulsants / Q000009:adverse effects*; D002220:Carbamazepine / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000627:therapeutic use; D003875:Drug Eruptions / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D057915:Drug Substitution; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy*; D006801:Humans; D018459:Lichen Sclerosus et Atrophicus / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D013256:Steroids / Q000008:administration & dosage; D016896:Treatment Outcome
D000927:Anticonvulsants; D013256:Steroids; C476610:oxcarbamazepine; D002220:Carbamazepine